Anlotinib as Third-Line or Later Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Real-World Efficacy and Safety Outcomes.
- DOI
- 10.2147/dddt.s584230
- Published
- 2026
- Container
- Drug design, development and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.2147/dddt.s584230,
title = {Anlotinib as Third-Line or Later Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Real-World Efficacy and Safety Outcomes.},
author = {Li Y and Li S and Li Y and Pan Z},
year = {2026},
journal = {Drug design, development and therapy},
doi = {10.2147/dddt.s584230},
url = {https://doi.org/10.2147/dddt.s584230}
}RIS
TY - JOUR TI - Anlotinib as Third-Line or Later Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Real-World Efficacy and Safety Outcomes. AU - Li Y AU - Li S AU - Li Y AU - Pan Z PY - 2026 JO - Drug design, development and therapy DO - 10.2147/dddt.s584230 UR - https://doi.org/10.2147/dddt.s584230 ER -
APA
Y, L., S, L., Y, L., & Z, P. (2026). Anlotinib as Third-Line or Later Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Real-World Efficacy and Safety Outcomes.. Drug design, development and therapy. https://doi.org/10.2147/dddt.s584230
Source records
- pubmed · retrieved 2026-09-26T20:57:42.610Z